- Home
- IBTA vs AVBP Comparison
IBTA vs AVBP Comparison
Compare IBTA & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- AVBP
- Stock Information
- Founded
- IBTA 2011
- AVBP 2021
- Country
- IBTA United States
- AVBP United States
- Employees
- IBTA N/A
- AVBP N/A
- Industry
- IBTA
- AVBP
- Sector
- IBTA
- AVBP
- Exchange
- IBTA Nasdaq
- AVBP NYSE
- Market Cap
- IBTA 892.4M
- AVBP 862.8M
- IPO Year
- IBTA 2024
- AVBP 2024
- Fundamental
- Price
- IBTA $37.62
- AVBP $20.17
- Analyst Decision
- IBTA Buy
- AVBP Strong Buy
- Analyst Count
- IBTA 10
- AVBP 8
- Target Price
- IBTA $74.60
- AVBP $38.38
- AVG Volume (30 Days)
- IBTA 333.1K
- AVBP 299.3K
- Earning Date
- IBTA 08-13-2025
- AVBP 08-13-2025
- Dividend Yield
- IBTA N/A
- AVBP N/A
- EPS Growth
- IBTA 24.66
- AVBP N/A
- EPS
- IBTA 2.03
- AVBP N/A
- Revenue
- IBTA $369,501,000.00
- AVBP N/A
- Revenue This Year
- IBTA $6.89
- AVBP $85.82
- Revenue Next Year
- IBTA $15.55
- AVBP N/A
- P/E Ratio
- IBTA $18.12
- AVBP N/A
- Revenue Growth
- IBTA 7.20
- AVBP N/A
- 52 Week Low
- IBTA $31.40
- AVBP $15.47
- 52 Week High
- IBTA $79.80
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- AVBP 38.35
- Support Level
- IBTA N/A
- AVBP $21.10
- Resistance Level
- IBTA N/A
- AVBP $22.29
- Average True Range (ATR)
- IBTA 0.00
- AVBP 1.02
- MACD
- IBTA 0.00
- AVBP -0.12
- Stochastic Oscillator
- IBTA 0.00
- AVBP 3.54
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.